Aller au contenu principal
Accès ouvert déclaré 2025 article

Anoikis- and m6A-related lncRNA analysis to identify prognostic indicators in liver hepatocellular carcinoma

0Citations signalées, ce qui n’est pas une note de qualité
2Institutions déclarées
2Pays d’affiliation déclarés

Rattachement africain : my, cn. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Background In cancer, the process of anoikis is intimately associated with the emergence and progression. N6-methyladenosine modification and m6A modification play an important role in regulating long non-coding RNAs. The liver hepatocellular carcinoma patients’ data, including clinical and prognostic data, were obtained via The Cancer Genome Atlas database. The univariate, multivariate Cox and Least Absolute Selection Operator (LASSO) regression were performed to gain anoikis- and m6A-related lncRNAs. The Kaplan-Meier method was employed to assess the overall survival rate for groups of high- and low risks. Results A signature comprising six anoikis- and m6A-related lncRNAs was constructed: AL117336.3, LINC01138, Z83851.1, NRAV, CASC19 and AC009283.1. The clinicopathological variables, the anoikis- and m6A-related lncRNA signature demonstrated superior diagnostic efficacy, with an area under the receiver operating characteristic curve of 0.810. In the high-risk group, the overall survival was shown to be inferior to that of in group of low risk, while patients were classified by distinct clinicopathological variables. The ssGSEA and CIBERSORT immune analysis demonstrated that the predictive signature was significantly associated with liver cancer patients’ immune status. The chemotherapy drugs ATRA, AUY922, bexarotene, gemcitabine, mitomycin-C, and PHA have been found to have greater sensitivity in treating high-risk patients. qRT-PCR showed that Z83851.1, NRAV and CASC19 lncRNAs were associated with poor prognosis and were high-risk factors. AC009283.1 lncRNA may have anti-cancer properties. Conclusions The predictive signature is capable of independently predicting the prognosis of liver cancer patients for understanding the mechanisms of anoikis- and m6A-related lncRNAs in liver hepatocellular carcinoma and offering clinical guidance to patients with liver cancer. How to cite: Yu P, Jing S, Dhillon SK. Anoikis and m6A related lncRNAs analysis to identify prognostic indicators in liver hepatocellular carcinoma. Electron J Biotechnol 2026;79. https://doi.org/10.1016/j.ejbt.2025.100701 .

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Anoikis- and m6A-related lncRNA analysis to identify prognostic indicators in liver hepatocellular carcinoma
Date Crossref
01/01/2026
Éditeur
Elsevier BV
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

RNA modifications and cancerCancer-related molecular mechanisms researchFerroptosis and cancer prognosis

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.